



PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/629,427
Filing Date	07/29/2003
First Named Inventor	Michael J. Yaszemski
Group Art Unit	
Examiner Name	

Sheet	1	of	2	Attorney Docket Number	630666.91012
-------	---	----	---	------------------------	--------------


[illegible][illegible]

8/31/05

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/629,427
		Filing Date	07/29/2003
		First Named Inventor	Michael J. Yaszemski
		Group Art Unit	
		Examiner Name	
Sheet 2	of 2	Attorney Docket Number	630666.91012

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-Issue number(s), publisher, city and/or country where published.	T ²
Wm		Olmarker et al., "Chondroitinase ABC (Pharmaceutical Grade) for Chemonucleolysis", Spine, 1996. 21:1952-56.	
		Bradbury et al., "Chondroitinase ABC promotes functional recovery after spinal cord injury", Nature, April 11, 2002, 416:636-40.	
		Zuo et al., "Regeneration of Axons after Nerve Transection Repair is Enhanced by Degradation of Chondroitin Sulfate Proteoglycan", Exp. Neurol., 2002. 176:221-28	
		Oldham et al., "Biological Activity of rhBMP-2 Released from PLGA Microspheres", Journal of Biomechanical Engineering, 2000. 122:289-292	
		Famdale, "Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue", Biochemica et Biophysica Acta, 1986. 883:173-77	

Examiner Signature		Date Considered	8/31/05
--------------------	--	-----------------	---------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.